BRPI0711646B8 - solução aquosa estéril de um sal de ácido succínico - Google Patents

solução aquosa estéril de um sal de ácido succínico

Info

Publication number
BRPI0711646B8
BRPI0711646B8 BRPI0711646A BRPI0711646A BRPI0711646B8 BR PI0711646 B8 BRPI0711646 B8 BR PI0711646B8 BR PI0711646 A BRPI0711646 A BR PI0711646A BR PI0711646 A BRPI0711646 A BR PI0711646A BR PI0711646 B8 BRPI0711646 B8 BR PI0711646B8
Authority
BR
Brazil
Prior art keywords
salt
aqueous solution
succinic acid
sterile aqueous
compound
Prior art date
Application number
BRPI0711646A
Other languages
English (en)
Inventor
S Ray Adrian
B Tumas Daniel
C Reiser Hans
S Chong Lee
A Lee William
j watkins William
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of BRPI0711646A2 publication Critical patent/BRPI0711646A2/pt
Publication of BRPI0711646B1 publication Critical patent/BRPI0711646B1/pt
Publication of BRPI0711646B8 publication Critical patent/BRPI0711646B8/pt
Publication of BRPI0711646C1 publication Critical patent/BRPI0711646C1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Processing Of Solid Wastes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

método e composições para tratar neoplasias malignas hematológicas. um composto de fórmula (1) e/ou seus sais, tautômeros e solvatos é usado para tratar neoplasias malignas hematológicas. em uma modalidade, um sal de ácido orgânico do composto 1 é provido para uso geral no tratamento de neoplasmas, e em uma modalidade adicional o sal é estabilizado com carboidrato.
BRPI0711646A 2006-05-16 2007-05-16 solução aquosa estéril de um sal de ácido succínico BRPI0711646C1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US80098306P 2006-05-16 2006-05-16
US60/800,983 2006-05-16
US83180506P 2006-07-18 2006-07-18
US60/831,805 2006-07-18
PCT/US2007/011726 WO2007136650A2 (en) 2006-05-16 2007-05-16 Method and compositions for treating hematological malignancies

Publications (4)

Publication Number Publication Date
BRPI0711646A2 BRPI0711646A2 (pt) 2011-11-29
BRPI0711646B1 BRPI0711646B1 (pt) 2020-12-01
BRPI0711646B8 true BRPI0711646B8 (pt) 2021-04-06
BRPI0711646C1 BRPI0711646C1 (pt) 2021-05-25

Family

ID=38578698

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0711646A BRPI0711646C1 (pt) 2006-05-16 2007-05-16 solução aquosa estéril de um sal de ácido succínico

Country Status (20)

Country Link
US (3) US20090258840A1 (pt)
EP (1) EP2020996B1 (pt)
JP (2) JP5544165B2 (pt)
KR (1) KR101424832B1 (pt)
CN (1) CN101442994B (pt)
AT (1) ATE534377T1 (pt)
AU (1) AU2007254309B2 (pt)
BR (1) BRPI0711646C1 (pt)
CA (1) CA2652048C (pt)
CY (1) CY1112377T1 (pt)
DK (1) DK2020996T3 (pt)
EA (1) EA016995B1 (pt)
ES (1) ES2377467T3 (pt)
HK (1) HK1127913A1 (pt)
MX (1) MX2008014665A (pt)
NZ (1) NZ572368A (pt)
PL (1) PL2020996T3 (pt)
PT (1) PT2020996E (pt)
SI (1) SI2020996T1 (pt)
WO (1) WO2007136650A2 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN101442994B (zh) * 2006-05-16 2013-03-06 吉里德科学公司 用于治疗恶性血液病的方法和组合物
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
KR20110067096A (ko) 2008-09-10 2011-06-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 및 관련 상태를 치료하기 위한 병용 요법
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
BR112012012641A2 (pt) 2009-11-27 2020-08-11 Boehringer Ingelheim International Gmbh TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
EP3366304B1 (en) 2010-06-24 2020-05-13 Boehringer Ingelheim International GmbH Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2013010964A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
EP3468562A1 (en) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
EP3808752A4 (en) * 2018-06-12 2022-03-09 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. PHOSPHONYMIDE ESTER COMPOUND, SALT THEREOF, RELATIVE CRYSTAL FORM THEREOF, PROCESS FOR THEIR PREPARATION AND THEIR USE
CN112168829B (zh) * 2020-09-24 2022-02-15 华南理工大学 抗病毒药物在制备治疗骨髓增生异常综合征药物中的应用及制得的骨髓增生异常综合征药物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
JP4651264B2 (ja) 2000-07-21 2011-03-16 ギリアード サイエンシーズ， インコーポレイテッド ホスホネートヌクレオチドアナログのプロドラッグならびにこれを選択および作製するための方法。
ATE369330T1 (de) * 2001-02-12 2007-08-15 Wyeth Corp O-desmethyl-venlafaxine succinat salz
ES2258652T3 (es) * 2001-11-29 2006-09-01 Pfizer Products Inc. Sales de succinato de 5,8,14-triazatetraciclo(10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de los mismos.
UA75482C2 (en) * 2001-12-12 2006-04-17 Pfizer Prod Inc Salts of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methylpyridine-3-yloxy)phenylamino]quinozaline -6-yl}alyl)acetamide, a method for the preparation and use thereof for the treatment of cancer
JP4476811B2 (ja) * 2002-05-13 2010-06-09 メタバシス・セラピューティクス・インコーポレイテッド Ｐｍｅａおよびそのアナログの新規ホスホン酸系プロドラッグ
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
BRPI0413595B8 (pt) * 2003-08-18 2021-05-25 H Lundbeck As sal de malonato, composição farmacêutica, uso de um sal de malonato, e, método de fabricação de um composto
CN1950383B (zh) * 2003-12-30 2010-06-09 吉里德科学公司 用于治疗病毒性疾病的膦酸酯、单膦酸酰胺化物、双膦酸酰胺化物
US20050239753A1 (en) 2004-01-21 2005-10-27 Gilead Sciences, Inc. Methods of inhibition of MMTV-like viruses
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
BRPI0619962A2 (pt) * 2005-12-16 2011-10-25 Wyeth Corp composições liofilizadas de um composto triazolopirimidina
CN101442994B (zh) * 2006-05-16 2013-03-06 吉里德科学公司 用于治疗恶性血液病的方法和组合物

Also Published As

Publication number Publication date
AU2007254309A1 (en) 2007-11-29
CA2652048A1 (en) 2007-11-29
BRPI0711646A2 (pt) 2011-11-29
US20110172192A1 (en) 2011-07-14
CN101442994B (zh) 2013-03-06
DK2020996T3 (da) 2012-02-27
ATE534377T1 (de) 2011-12-15
KR20090015122A (ko) 2009-02-11
EA200802333A1 (ru) 2009-04-28
ES2377467T3 (es) 2012-03-27
BRPI0711646C1 (pt) 2021-05-25
PL2020996T3 (pl) 2012-04-30
KR101424832B1 (ko) 2014-08-06
CN101442994A (zh) 2009-05-27
US20080039427A1 (en) 2008-02-14
JP2013100324A (ja) 2013-05-23
SI2020996T1 (sl) 2012-03-30
US20090258840A1 (en) 2009-10-15
AU2007254309B2 (en) 2012-05-03
US8435969B2 (en) 2013-05-07
CA2652048C (en) 2012-12-11
HK1127913A1 (en) 2009-10-09
CY1112377T1 (el) 2015-12-09
EP2020996A2 (en) 2009-02-11
PT2020996E (pt) 2012-02-20
EA016995B1 (ru) 2012-09-28
JP5544165B2 (ja) 2014-07-09
NZ572368A (en) 2011-04-29
WO2007136650A3 (en) 2008-01-24
WO2007136650A2 (en) 2007-11-29
BRPI0711646B1 (pt) 2020-12-01
MX2008014665A (es) 2008-11-28
EP2020996B1 (en) 2011-11-23
JP2009537539A (ja) 2009-10-29

Similar Documents

Publication Publication Date Title
BRPI0711646B8 (pt) solução aquosa estéril de um sal de ácido succínico
PE20090770A1 (es) Derivados de benzoxazolona
TR201900306T4 (tr) Mek inhibitörlerini kullanma yöntemleri.
BRPI0913291A2 (pt) composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto
EA200801630A1 (ru) Соединения пиперазина с гербицидным действием
BR112015009850A2 (pt) compostos de piridila substituídos por heteroarila úteis como moduladores de quinase
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
CY1111721T1 (el) Ακυλαμινοπυραζολια ως αναστολεις fgfr
ES2531190T3 (es) Método para producir un compuesto de 4-oxoquinolina
BRPI0821653B8 (pt) composto de piridina substituída com anel heterocíclico e grupo fosfonoximetila ou um sal do mesmo, composição farmacêutica compreendendo-os e uso dos mesmos para tratar uma doença fungíca
BRPI0713378A8 (pt) composto, pró-droga, modulador da função do receptor gpr40, agente farmacêutico uso do composto, e, método de produção de uma forma opticamente ativa de um composto
BRPI0621386B8 (pt) composição farmacêutica para o uso externo
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
NO20065416L (no) Hemming av fremstillingen av biogene sulfider via kombinasjoner av biocide og metabolske inhibitorer
NI201100223A (es) Derivados de imidazolidina 2 -0ne 1,3 - disustituidos como inhibidores de cyp 17
ECSP099330A (es) Compuesto de indol
CY1117659T1 (el) Υδατικο διαλυμα που περιλαμβανει 3-κινουκλιδινονες για τη θεραπεια υπερπλαστικης, αυτοανοσης και καρδιακης ασθενειας
ECSP11011165A (es) Compuesto heterocíclico y uso del mismo
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
ECSP099073A (es) Nuevos derivados de piridazina
CL2011000135A1 (es) Uso de una fromulacion farmaceutica acuosa que comprende 0,5-10% de terbinafina o una sal de la misma, 2-10% de un fosfolipido y 1-5% de un surfactante, para preparar un medicamento util para tratar una infeccion fungica; formulacion farmaceutica.
BR112013028598A2 (pt) método para promover o crescimento de plantas
BR112013010918A2 (pt) sal de alumínio contendo elevada percentagem de al30
BR112012006172A2 (pt) derivados de alqueno oxindol e seus usos para o tratamento de obesidade, diabetes e hiperlipidemia
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2604 DE 01/12/2020 QUANTO AO ENDRECO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/05/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF